Rhinomed (ASX:RNO) To Present At World Leading Biotech Convention, 2015 BIO

Melbourne, May 18, 2015 - (ABN Newswire) - Rhinomed Ltd (ASX:RNO) is pleased to announce that it has been accepted as a presenter at 2015 BIO, the world's leading biotech convention to be held in Philadelphia, June 15-18th.

KEY HIGHLIGHTS:

- Rhinomed accepted as a speaker at Global 2015 BIO Convention, Philadelphia, USA June 1518

- Company to showcase sleep and drug delivery platform advances

- Continuing on from successful recent distribution deals; reflects major push into global sleep and drug delivery markets

BIO is one of the premier global biotech conferences. It is attended by over 15,000 biotech and pharma leaders and provides an important opportunity for the company to expose its patented nasal platform technology to a broader range of potential partners and distributors.

With clear progress being made within its Sport and Sleep business units, the imminent start of the sleep apnoea trial featuring its new INPEAP technology, and progress in the drug delivery program, the business is receiving strong interest globally.

"BIO is a great opportunity to extend the conversations we are already having with a range of parties. It is also provides a great opportunity to introduce our platform to a much broader set of the world's leading biotech and pharma companies," commented CEO Michael Johnson.

"Rhinomed's internal nasal platform is rapidly gaining acceptance with thousands of users in both sport and sleep. With this growing level of acceptance, the platform provides a highly attractive, patented and derisked delivery platform for sleep and drug development companies and pharma," Johnson said.

The company will be travelling and exhibiting as part of the Victorian Government's delegation to 2015 BIO.

WEB: Rhinomed to Present at 2015 BIO

About: Rhinomed Ltd

Rhinomed Limited is a medical technology firm that focuses on nasal, respiratory and breathing management technologies. The company is monetising its technology portfolio in the Sport and recreation market, Sleep, Wellbeing and Drug delivery markets.

Rhinomed's technology is designed to radically improve the way you breathe sleep, maintain your health and take medication.

The first product brought to market is the Turbine(TM). A radical nasal technology that improves airflow by an average of 38%, the Turbine(TM) is an internal nasal dilator that has since it's launch in January 2014 in Australia, grown to be widely adopted by leading cyclists and triathletes globally.

Now shipped to over 36 countries and with a growing global distribution base, the Turbine(TM) is providing all those undertaking aerobic activities with an opportunity to breathe better, perform better and get more enjoyment from their sport and exercise.

Help employers find you! Check out all the jobs and post your resume.

Back to news